This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

​GSK-Pfizer deal wins New Zealand regulatory approval

( April 30, 2019, 05:12 GMT | Official Statement) -- MLex Summary: GlaxoSmithKline’s plan to acquire Pfizer’s consumer healthcare business won regulatory approval today in New Zealand after the country's competition regulator said it would not substantially lessen competition in any of the country's markets. The New Zealand Commerce Commission said GSK and Pfizer aren't close competitors in the supply of cold and flu treatments, systemic pain-relief or any other consumer healthcare products, and other market competitors will probably constrain a merged entity.The commission's full statement follows: ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login